The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving…

By P. Hesketh, S. Grunberg, R. Gralla, D. Warr, F. Roila, R. de Wit, S. Chawla, A. Carides, Juliana Ianus, M. Elmer and 4 more. Journal of Clinical Oncology, 2003

776 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/c297284fdd8feb958e6733185d5c5317eefd4b8b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Somerfield
2. J. Koeller
3. G. Morrow
4. L. Chinnery
5. Maurice Chesney
6. S. Grunberg

Citations in the corpus

• American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. (2006, methodology): “In placebo-controlled phase III trials of 1,053 randomly assigned patients receiving cisplatin, 72% of individuals receiving the combination of aprepitant and dexamethasone had no delayed vomiting or rescue compared with 51% receiving dexamethasone alone.(33,34) In 866 patients receiving the combina”